You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Investigational Drug Information for Camostat


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Camostat?

Camostat is an investigational drug.

There have been 24 clinical trials for Camostat. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.

The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Stanford University, Heinrich-Heine University, Duesseldorf, and Yale University.

There are one hundred and fifty-two US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Camostat
TitleSponsorPhase
Camostat Mesylate for Protein-losing Enteropathy After Fontan OperationSeoul National University HospitalPhase 2
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsOno Pharmaceutical Co. LtdPhase 1/Phase 2
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsYale UniversityPhase 1/Phase 2

See all Camostat clinical trials

Clinical Trial Summary for Camostat

Top disease conditions for Camostat
Top clinical trial sponsors for Camostat

See all Camostat clinical trials

US Patents for Camostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Camostat ⤷  Try a Trial Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof Signature Therapeutics, Inc. (San Carlos, CA) ⤷  Try a Trial
Camostat ⤷  Try a Trial Substituted pyridines and method of use AbbVie S.a.r.l. (Luzembourg, LU) Galapagos NV (Mechelen, BE) ⤷  Try a Trial
Camostat ⤷  Try a Trial Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity Parion Sciences, Inc. (Durham, NC) ⤷  Try a Trial
Camostat ⤷  Try a Trial Crystallization method and bioavailability GRUNENTHAL GMBH (DE) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Camostat

Drugname Country Document Number Estimated Expiration Related US Patent
Camostat Australia AU2010293028 2029-09-08 ⤷  Try a Trial
Camostat Brazil BR112012005124 2029-09-08 ⤷  Try a Trial
Camostat Canada CA2773340 2029-09-08 ⤷  Try a Trial
Camostat China CN102695545 2029-09-08 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.